Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years - PubMed (original) (raw)

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

Vincent Wai-Sun Wong et al. Gut. 2010 Jul.

Abstract

Background: Patients with non-alcoholic steatohepatitis (NASH) have increased mortality and liver-related complications. In contrast, simple steatosis is considered benign and non-progressive.

Objective: To investigate disease progression in patients with different degrees of non-alcoholic fatty liver disease (NAFLD) activity.

Design: Prospective longitudinal hospital-based cohort study.

Patients: Fifty-two patients (age 44+/-9 years) with biopsy-proven NAFLD had liver biopsies repeated at month 36.

Results: Among 13 patients with simple steatosis at baseline, 2 (15%) had a normal liver at month 36, 3 (23%) continued to have simple steatosis, 5 (39%) developed borderline NASH and 3 (23%) developed NASH. Among 22 patients with borderline NASH at baseline, 4 (18%) had simple steatosis and 13 (59%) had borderline NASH at month 36, while 5 (23%) developed NASH. Among 17 patients with NASH at baseline, 10 (59%) continued to have NASH and 6 (35%) had borderline NASH at month 36. Only 1 (6%) patient regressed to simple steatosis. Overall, 14 (27%) patients had fibrosis progression, 25 (48%) had static disease, and 13 (25%) had fibrosis regression. Reduction in body mass index and waist circumference was independently associated with non-progressive disease activity and fibrosis. The baseline serum levels and month 36 changes in adiponectin, tumour necrosis factor alpha, interleukin 6 and leptin were not associated with disease progression. Serum cytokeratin-18 fragment level reflected disease activity and its change correlated with the change in NAFLD activity score (R=0.51, p<0.001).

Conclusions: Patients with simple steatosis may still develop NASH and fibrosis progression. Weight reduction is associated with non-progressive disease. All patients with NAFLD should undergo periodic assessment and lifestyle modification.

PubMed Disclaimer

Cited by

Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.
Lu ZY, Shao Z, Li YL, Wulasihan M, Chen XH. Lu ZY, et al. World J Gastroenterol. 2016 Apr 7;22(13):3663-9. doi: 10.3748/wjg.v22.i13.3663. World J Gastroenterol. 2016. PMID: 27053858 Free PMC article.
Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance.
Berk PD, Verna EC. Berk PD, et al. Clin Liver Dis. 2016 May;20(2):245-62. doi: 10.1016/j.cld.2015.10.007. Epub 2016 Feb 18. Clin Liver Dis. 2016. PMID: 27063267 Free PMC article. Review.
NAFLD in Asia--as common and important as in the West.
Farrell GC, Wong VW, Chitturi S. Farrell GC, et al. Nat Rev Gastroenterol Hepatol. 2013 May;10(5):307-18. doi: 10.1038/nrgastro.2013.34. Epub 2013 Mar 5. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23458891 Review.
Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Mikolasevic I, et al. World J Gastroenterol. 2016 Aug 28;22(32):7236-51. doi: 10.3748/wjg.v22.i32.7236. World J Gastroenterol. 2016. PMID: 27621571 Free PMC article. Review.

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years - PubMed (original) (raw)